LBDA

DLB Study at Columbia University

Targeting Lewy Body Specific Pathology using Biomarkers
 

What is this study about?

The aim of this study is to develop better biomarkers for diagnosis and treatment of Lewy body disorders. In particular, there is a need to understand how the contribution of co-existing Alzheimer’s disease may affect the diagnosis and clinical course of dementia with Lewy bodies (DLB).

What is involved?

This study will recruit a group of individuals with DLB.. There will be up to 6 office visits over the 5 years. Participants will have a comprehensive neurological evaluation which will include donation of blood, urine, and cerebrospinal fluid samples.

Who can participate?

An individual may be able to take part in the trial if he/she:

  • Has been diagnosed with dementia with Lewy bodies (DLB)
  • Speaks English or Spanish
  • Is able to provide their own consent to participate in the study at the first visit

Study Sponsor

The U.S. National Institutes of Health

For more information

Contact:
Martha Orbe-Reilly MD (coordinator)
Telephone (212)305-8873
mo404@cumc.columbia.edu
 
Helen Mejia-Santana MS (coordinator)
Telephone (212) 305-9183
hm28@cumc.columbia.edu